SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-21-001707
Filing Date
2021-02-25
Accepted
2021-02-25 07:01:18
Documents
13
Period of Report
2021-02-25
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kala-20210225x8k.htm   iXBRL 8-K 33445
2 EX-99.1 kala-20210225xex99d1.htm EX-99.1 227379
  Complete submission text file 0001558370-21-001707.txt   402974

Data Files

Seq Description Document Type Size
3 EX-101.SCH kala-20210225.xsd EX-101.SCH 3030
4 EX-101.LAB kala-20210225_lab.xml EX-101.LAB 16737
5 EX-101.PRE kala-20210225_pre.xml EX-101.PRE 10609
6 EXTRACTED XBRL INSTANCE DOCUMENT kala-20210225x8k_htm.xml XML 5061
Mailing Address 490 ARSENAL WAY SUITE 120 WATERTOWN MA 02472
Business Address 490 ARSENAL WAY SUITE 120 WATERTOWN MA 02472 781-996-5252
Kala Pharmaceuticals, Inc. (Filer) CIK: 0001479419 (see all company filings)

IRS No.: 270604595 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38150 | Film No.: 21676353
SIC: 2834 Pharmaceutical Preparations